Published Date: 08 Mar 2023
A group of scientists led by Dr. Yamin Zhang and Dr. Colin Franz of Shirley Ryan AbilityLab and Dr. John Rogers of Northwestern University have developed a new technique. Change...
Read Full NewsA recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.
The newly approved inhibitor is for patients who previously received another drug of the same class.
1.
Rural-urban disparities seen in cervical cancer
2.
When does a melanoma metastasize? Implications for management
3.
Blood Test Flags Mantle Cell Lymphoma Relapse Before PET-CT
4.
NP-Led Outreach Ups Cancer Screening in Rural Women Veterans
5.
New Immune Therapy Boosts Disease Control in Prostate Cancer
1.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
2.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
3.
The Latest Research on Basal Cell Carcinoma: New Developments in Diagnosis and Cure
4.
Intravenous Calcium for Reducing Blood Loss During Cesarean Delivery: A Review of Current Evidence
5.
Segmental vs. Non-Segmental Vitiligo: What’s the Difference?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation